Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Most cells in the human body each contain about six feet of DNA. Yet the nucleus, where DNA is coiled, is no larger than a ...

According to new research next-generation DNA sequencing (NGS) -- the same technology which is powering the development of tailor-made medicines, cancer diagnostics, infectious disease tracking, and ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

How are advanced diagnostics benefitting patients? Our recent webinar discussed next-gen molecular analysis in precision ...

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.